))
Neurology Edition: Top Headlines for Week of May 23, 2023
Manage episode 407442270 series 3560281
Konten disediakan oleh Healio. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Healio atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
In this edition, FDA approves supplemental new drug application for Rexulti, early amyloid PET provides high diagnostic confidence, Leqembi reduced biomarkers of Alzheimer’s and more.
Read the full coverage here:
FDA approves supplemental new drug application for Rexulti to treat Alzheimer's agitation
Early amyloid PET provides high diagnostic confidence for adults with cognitive impairment
Leqembi reduced biomarkers of Alzheimer’s, slowed cognitive decline at 18 months
FDA grants 510(k) clearance for self-directed EEG headset
Oral Bruton’s tyrosine kinase inhibitor reduced brain lesions in phase 2 MS trial
References:
Altomare D, et al. JAMA Neurol. 2023;doi:10.1001/jamaneurol.2023.0997.
Van Dyck CH, et al. A study to confirm safety and efficacy of lecanemab in participants with early Alzheimer’s disease (Clarity AD). Presented at: American Academy of Neurology annual meeting; April 22-27, 2023; Boston.
117 episode
Bagikan
